Samsung Biologics Earns an Integrated ESG Rating of A+... Ranks Among Top 1.8% of Listed Companies in Korea

[Financial News] Samsung Biologics has earned an integrated A+ rating in a domestic ESG assessment, placing it among the top 1.8% of companies. The result reflects improved scores across all three areas—environmental, social and governance. After earning high marks in global ESG assessments, the company has also secured a high rating in a domestic assessment, earning recognition for its sustainability management capabilities.
Samsung Biologics said on the 13th that it received an integrated A+ rating in the 2026 ESG assessment announced by the Korea Institute of Corporate Governance and Sustainability (KCGS). The rating is one notch higher than last year’s, placing the company among the top 1.8% of the 1,020 listed companies assessed.
No company received the top S rating in this year’s assessment, while a total of 18 companies, including Samsung Biologics, earned an A+ rating. The Korea Institute of Corporate Governance and Sustainability assesses the level of ESG management at domestic companies and assigns one of seven grades, from S to D. The results are used in institutional investors’ investment risk analyses and in selecting constituents for Korea Exchange ESG indices.
By category, Samsung Biologics received A+ ratings in environmental and social performance and an A in governance.
In the environmental category, the assessment took into account the company’s setting and disclosure of targets to reduce greenhouse gas emissions, as well as its efforts to cut emissions and water use in production. In the social category, it received positive marks for improving its human rights management system and expanding disclosures related to fair-trade training. In governance, it was recognized for improving the transparency of its board and audit committee operations.
The company is also continuing to post strong results in global assessments. Last November, Samsung Biologics received the highest rating in Sustainalytics’ ESG risk assessment, and in September it earned an A rating in the Morgan Stanley Capital International (MSCI) ESG assessment.
Samsung Biologics CEO John Rim said, "This assessment result will serve as an opportunity to strengthen ESG risk management capabilities and build market trust," adding, "I will contribute to enhancing long-term corporate value through transparent and responsible ESG management."

[email protected] Jung Sang-hee Reporter